Get the Stockscreener App
1.05
0.96%
0.01
Pre-market:
1.05
Oncolytics Biotech Inc stock is traded at $1.05, with a volume of 914.15K.
It is up +0.96% in the last 24 hours and down -11.02% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$1.04
Open:
$1.06
24h Volume:
914.15K
Relative Volume:
0.89
Market Cap:
$110.39M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-3.9698
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
-1.87%
1M Performance:
-11.02%
6M Performance:
+124.55%
1Y Performance:
+7.14%
1-Day Range:
$1.03
$1.09
1-Week Range:
$1.0244
$1.15
52-Week Range:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.05 | 110.39M | 0 | -20.31M | -21.07M | -0.2645 |
|
ARGX
Argen X Se Adr
|
929.61 | 55.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.02 | 110.91B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
197.40 | 41.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
376.63 | 40.48B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.31 | 72.89B | 14.25B | 4.58B | 3.88B | 41.77 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech Forms Advisory Board to Advance Pelareorep in GI Cancers - TipRanks
Oncolytics Biotech stock price target doubled to $10 by H.C. Wainwright - Investing.com
Oncolytics Biotech (ONCY) Price Target Raised by HC Wainwright | - GuruFocus
The 5-Minute Investor Podcast, Ep. 37: Cancer-fighting stocks | 2025-11-17 | Investing News - Stockhouse
Why Oncolytics Biotech Inc. is moving today2025 Geopolitical Influence & Low Risk High Win Rate Picks - newser.com
Using Ichimoku Cloud for Oncolytics Biotech Inc. technicalsMarket Risk Analysis & Free Real-Time Market Sentiment Alerts - newser.com
Using data tools to time your Oncolytics Biotech Inc. exitBuy Signal & Fast Moving Stock Watchlists - newser.com
Visual trend scoring systems applied to Oncolytics Biotech Inc.Portfolio Performance Summary & AI Based Buy/Sell Signal Reports - newser.com
Is Oncolytics Biotech Inc a good long term investmentVolume Analysis Techniques & Capital Growth Strategies - earlytimes.in
Can Kashyap Tele Deliver on Promised Growth AmbitionsMarket Volatility Update & Affordable Portfolio Building - earlytimes.in
What Analyst Ratings Reveal About Mafatlal Industries Limiteds Future ValueHigh Beta Stocks & Free Robust Financial Gains - earlytimes.in
Will Oncolytics Biotech Inc. outperform the marketJuly 2025 Volume & Growth Focused Stock Reports - newser.com
How to interpret RSI for Oncolytics Biotech Inc. stockM&A Rumor & High Accuracy Swing Trade Signals - newser.com
Can you recover from losses in Oncolytics Biotech Inc.2025 Performance Recap & AI Powered Buy/Sell Recommendations - newser.com
Oncolytics Biotech (NASDAQ:ONCY) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
What recovery options are there for Oncolytics Biotech Inc.July 2025 Highlights & Risk Managed Investment Strategies - newser.com
Analyzing Oncolytics Biotech Inc. with risk reward ratio chartsTrade Risk Summary & Risk Controlled Stock Pick Alerts - newser.com
Can Oncolytics Biotech Inc. stock rebound after recent weakness2025 Top Decliners & Long-Term Safe Investment Plans - newser.com
Will Oncolytics Biotech Inc. stock keep outperforming rivalsEarnings Beat & High Accuracy Swing Entry Alerts - newser.com
Will Oncolytics Biotech Inc. stock reach Wall Street targetsJuly 2025 Institutional & Real-Time Stock Movement Alerts - newser.com
Heatmap analysis for Oncolytics Biotech Inc. and competitorsWeekly Risk Report & Fast Exit Strategy with Risk Control - newser.com
Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Is Oncolytics Biotech Inc. stock gaining market sharePortfolio Value Summary & Low Volatility Stock Suggestions - newser.com
Identifying reversal signals in Oncolytics Biotech Inc.2025 Momentum Check & High Win Rate Trade Alerts - newser.com
Will Oncolytics Biotech Inc. stock recover faster than peersJuly 2025 Volume & AI Powered Buy and Sell Recommendations - Fundação Cultural do Pará
What makes BioCardia, Inc. stock price move sharply - newser.com
Combining price and volume data for Oncolytics Biotech Inc.July 2025 Action & Verified Swing Trading Watchlist - newser.com
Oncolytics Biotech Reports Increased Q3 Loss Amid Rising Expenses - TipRanks
What analysts say about Oncolytics Biotech Inc stockVolatility Trading Techniques & Affordable Market Insights - earlytimes.in
Is Oncolytics Biotech Inc. stock overvalued by current metricsLayoff News & Free Community Supported Trade Ideas - newser.com
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.99%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):